XenoGesis and Sygnature Discovery to Host Meeting

XenoGesis is teaming up with Sygnature Discovery and DMDG to host the forthcoming meeting on predictive toxicology in Discovery DMPK.

The one-day meeting will be held at BioCity, Nottingham on Thursday 22nd March 2018.

The meeting will provide a forum for the exchange of ideas between members of the DMPK and toxicology research communities. The event will bring together talks from thought leaders in industry and academia to provide global perspectives on how predictive toxicology platforms have evolved and become key to the drug discovery and development process.

XenoGesis and Sygnature Discovery will be joined by speakers from the University of Birmingham, ApconiX, AstraZeneca, University of Swansea, Envigo and Imperial College.

Read more here: XenoGesis and Sygnature Discovery to Host DMDG Meeting: Predictive Toxicology in Discovery DMPK 

 

By |2018-07-11T12:06:23+00:00February 22nd, 2018|Events|Comments Off on XenoGesis and Sygnature Discovery to Host Meeting

About the Author:

Dr Richard Knight PhD, ERT, is a Director and Co-founder of ApconiX, a preclinical toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts. Richard graduated from the University of Bradford in 1989 with a degree in Biomedical Sciences (Pharmacology) before gaining a PhD at the University of Leeds researching the role of adenosine receptors in renal function and toxicity. His research then included post-doctoral studies at University of California, Los Angeles (UCLA) into the effects of ischaemia/reperfusion injury on cardiac metabolism. Richard joined Zeneca Pharmaceuticals, Safety of Medicines Group in 1996 as a Study Director, and then Project Toxicologist across multiple therapy areas, from early discovery through to market. As Lead Toxicologist for Oncology, Richard was a member of both the Drug Safety and Metabolism, and Oncology Leadership teams with responsibility for safety across the AZ oncology portfolio. In this senior role he provided leadership and mentoring support to other project toxicologists. Richard has worked on many drug platforms over this time including small molecules, biologics, proteins and oligonucleotides and has been involved in bringing over 30 new candidate drugs into clinical trials and 5 to marketing approval.